Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | USP28 | Q96RU2 | 4/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.41 |
| ▸ | USP25 | Q9UHP3 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8250737 | 0.81 | HTR6 (0.45) | MAPKAPK2HTR6ALDH1A1USP28OPRL1 | |
| SCHEMBL12828065 | 0.79 | HTR6 (0.46) | MAPKAPK2HTR6ALDH1A1USP28OPRL1 | |
| SCHEMBL5023862 | 0.78 | ALDH1A1 (0.45) | MAPKAPK2HTR6ALDH1A1USP28OPRL1 | |
| SCHEMBL18052714 | 0.78 | HTR6 (0.50) | HTR6ALDH1A1USP28OPRL1USP25 | |
| SCHEMBL8256296 | 0.75 | USP28 (0.47) | MAPKAPK2HTR6ALDH1A1USP28USP25 | |
| SCHEMBL8250845 | 0.74 | HTR6 (0.54) | MAPKAPK2HTR6OPRL1MAPTLMNA | |
| SCHEMBL8437508 | 0.74 | ALDH1A1 (0.49) | MAPKAPK2HTR6ALDH1A1OPRL1MAPT | |
| SCHEMBL8259609 | 0.74 | ALDH1A1 (0.58) | HTR6ALDH1A1MAPTLMNAGAA | |
| SCHEMBL8250929 | 0.74 | HTR6 (0.43) | MAPKAPK2HTR6ALDH1A1USP28OPRL1 | |
| SCHEMBL8250761 | 0.74 | HTR6 (0.45) | MAPKAPK2HTR6ALDH1A1USP28OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | MAPKAPK2 2250/4885HTR6 44/4885ALDH1A1 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.